HER3, PI3K, and JAK2 pathway activation on reverse phase protein microarray (RPMA) in HER2-amplified residual disease (RD) refractory to preoperative chemotherapy plus trastuzumab (H), lapatinib (L), or both (HL).
2015 ◽
Vol 33
(15_suppl)
◽
pp. 621-621
2011 ◽
Vol 416
(2)
◽
pp. 145-151
◽
Keyword(s):
2010 ◽
2015 ◽
2004 ◽
Vol 84
(2)
◽
pp. 235-244
◽
Keyword(s):
Keyword(s):